ID: ALA3828051

Max Phase: Preclinical

Molecular Formula: C25H26N2O5S

Molecular Weight: 466.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(CC[C@H](NS(=O)(=O)c1ccc(-c2ccccc2)cc1)C(=O)O)NCCc1ccccc1

Standard InChI:  InChI=1S/C25H26N2O5S/c28-24(26-18-17-19-7-3-1-4-8-19)16-15-23(25(29)30)27-33(31,32)22-13-11-21(12-14-22)20-9-5-2-6-10-20/h1-14,23,27H,15-18H2,(H,26,28)(H,29,30)/t23-/m0/s1

Standard InChI Key:  ZWFVIZGPXNSREN-QHCPKHFHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 466.56

Molecular Weight (Monoisotopic): 466.1562

AlogP: 3.22

#Rotatable Bonds: 11

Polar Surface Area: 112.57

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.33

CX Basic pKa:

CX LogP: 3.57

CX LogD: 0.15

Aromatic Rings: 3

Heavy Atoms: 33

QED Weighted: 0.40

Np Likeness Score: -0.67

References

1. Adhikari N, Halder AK, Mallick S, Saha A, Saha KD, Jha T..  (2016)  Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.,  24  (18): [PMID:27452283] [10.1016/j.bmc.2016.07.023]

Source

Source(1):

• Scientific Literature